Why Edgewise Therapeutics Is Rising In Pre-market?

Edgewise Therapeutics, Inc., (EWTX) reported positive topline results from the BMD,
or phase 1b, portion of a first-in-human phase 1 trial assessing EDG-5506, an orally
administered small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy and BMD.

In study, the seven adults with BMD were administered 20 mg oral doses of EDG-5506 or placebo. EDG-5506 was shown to be well-tolerated with no discontinuations or dose reductions. Also, treatment with EDG-5506 led to a significant and time-dependent decrease in key biomarkers of muscle damage. Dosing with EDG-5506 was not found to affect voluntary grip, shoulder, or hip strength.

“We believe the magnitude of reduction in multiple key biomarkers of muscle damage in adults with BMD after only two weeks of dosing is unprecedented,” said Kevin Koch, CEO of Edgewise.

Shares of Edgewise Therapeutics were up 20% in pre-market trade on Wednesday.

Disney+ Unveils Trailer And Poster For ‘The Ice Age Adventures Of Buck Wild’

The animation movie studio, Disney+ adds another movie to the Ice Age franchise named the ‘The Ice Age Adventures of Buck Wild’ which is set to come out by the end of January. Disney+ has released the trailer earlier this week.

The movie will rotate around the character of Buck the weasel (voiced by Simon Pegg) who was introduced in the fifth installment of the franchise Ice Age: Dawn of The Dinosaurs released almost 6 years back. The trailer shows Buck as an alpha who is not afraid of daunting situations but ultimately requires rescuing by the familiar Ice Age heroes Manny, Ellie, Sid, and Diego.

The film is also set in The Lost World where the weasels live in “the most dangerous place on Earth”, living a life of constant struggle amongst the huge predators and other life-threatening traps “to save the Lost World from dinosaurs domination”.

Simon Pegg has also played as a voice actor in Mission: Impossible- Fallout will be joined by Utkarsh Ambudkar (Free Guy), Justina Machado (One Day at a Time), Vincent Tong (Ninjago), and Aaron Harris. John C. Donkin is the director of the film and it is written by Jim Hecht (Ice Age: The Meltdown), Ray DeLaurentis (Fairly Odd Parents), and Will Schifrin (Bunsen Is a Beast) from a story by Jim Hecht.

The movie is set to stream on Disney+ on January 28. The platform has five other movies of the franchise and two more specials.

Sodexo Q1 Sales Rise On Recovery In Demand; Backs FY22 View

Sodexo S.A. (SDXAY.PK), a French food services and facilities management company, posted a rise in sales for the first quarter, amidst recovery in consumer demand. The company has reiterated its guidance for the current fiscal, citing higher sales and positive market cues.

For the first three-month period of fiscal 2022, the Paris-headquartered firm reported its total revenue at 5.26 billion euros, a rise of 18.8 percent, compared to the same period a year ago.

In addition, the company’s business and administration, education, and onsite services posted a double digit growth for the quarter.

Accordingly, business and administration, education, and onsite services reported revenues of 2.61 billion euros, 1.12 billion euros, and 5.08 billion euros, respectively, a rise of 19.8 percent, 22.7 percent, and 19.2 percent compared to the first quarter of 2021.

Owing to positive market sentiments, the French company has reiterated its guidance for the fiscal year 2022. Sodexo expects its organic growth to be in the range of 15 percent – 18 percent, and underlying operating margin of close to 5 percent, at constant rates.

ObsEva: Linzagolix Phase 3 Trial Shows Positive Topline Results In Women With Moderate-to-severe EAP

ObsEva SA (OBSV), a Swiss biopharmaceutical company focused on women’s health, announced Thursday positive topline results from the Phase 3 EDELWEISS 3 trial of linzagolix in women with moderate-to-severe endometriosis-associated pain or EAP.

Linzagolix is an oral GnRH antagonist. In the trial, two doses were tested, a 200 mg once-daily dose of linzagolix in combination with add-back therapy or ABT and a 75 mg dose of linzagolix without ABT.

The company said the results support continued development of linzagolix with ABT and non-ABT doses for the treatment of endometriosis.

The once daily linzagolix 200 mg dose met the co-primary efficacy objectives, demonstrating reductions in dysmenorrhea or DYS and non-menstrual pelvic pain or NMPP at 3 months.

The 75 mg dose without ABT demonstrated a statistically significant reduction versus placebo in DYS at 3 months.

Both linzagolix doses were generally well-tolerated with minimal BMD decrease and few adverse events occurring in more than 5% of patients up to 6 months.

Additional data from the post-treatment follow-up of EDELWEISS 3 are expected in the second quarter and from the post-treatment follow-up of the extension study in the fourth quarter.

Crude Oil Extends Upward Move, Reaching Highest Levels In A Month

Crude oil prices showed a notable advance during trading on Wednesday, extending the upward move seen throughout the New Year.

After surging $0.91 or 1.2 percent to $76.99 a barrel in the previous session, crude for February delivery jumped $0.86 or 1.1 percent to $77.85 a barrel.

The price of crude oil reached its highest levels in over a month amid continued optimism the Omicron variant of the coronavirus will not significantly impact global demand.

Meanwhile, traders largely shrugged off a report from the Energy Information Administration showing U.S. crude oil inventories decreased by less than expected in the week ended December 31st.

The report showed crude oil inventories fell by 2.1 million barrels last week versus expectations for a decrease of about 3.3 million barrels.

The EIA also said gasoline inventories spiked by 10.1 million barrels, while distillate fuel inventories increased by 4.4 million barrels.